Navigation Links
Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Date:10/19/2007

-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfull
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MITI ) ("Micromet" or the "Company"), a ... of cancer,inflammation and autoimmune diseases, today announced that ... appointed Dr. Peter Johann, a,current member of the ... Company,s,audit committee. The appointment fills the vacancy left ...
... ALTO, Calif., Sept. 15 Varian, Inc.,(NasdaqGS: VARI) ... promoted,Sean M. Wirtjes, Vice President and Controller, to ... September 15, 2008. Wirtjes,assumes the Treasurer position from ... Vice President and Chief Financial Officer., The ...
... Inc.,(Amex: PIP ) a biodefense company ... countermeasures against chemical and,biological threats, announced today ... of Health and Human Services (DHHS) that ... anthrax vaccine,SparVax(TM), has completed a comprehensive technical ...
Cached Biology Technology:Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Varian, Inc. Board of Directors Makes Officer Changes 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 3PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 4
(Date:4/23/2014)... release is available in French and German . ... or female? In humans and other mammals, the difference between sexes ... It is present only in males, where the two sexual chromosomes ... the Y is ultimately responsible for all the morphological and physiological ... been the case. A very long time ago, the X and ...
(Date:4/23/2014)... Huntington,s disease, most in their mid-thirties and forties, ... behavioral decline within two decades. "Mutant" protein clusters, ... disease, have been the primary focus of therapies ... new research from Prof. Gerardo Lederkremer and Dr. ... Cell Research and Immunology, in collaboration with Prof. ...
(Date:4/23/2014)... A team of researchers in Korea who ... brains of nonhuman primates and assessed cell survival ... that the hNSCs had differentiated into neurons at ... The study will be published in a future ... currently freely available on-line as an unedited early ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Biology in the College of Arts and Science at ... 2011 Fitch Award for Excellence in Herpetology from the ... individuals who have demonstrated long-term excellence in the study ... of amphibian ecology and wetland conservation, Semlitsch is well-known ...
... When an animal gets too hot or too cold, or feels ... where it,s cooler or hotter, or to the nearest place where ... life? What can a plant do under similar circumstances? ... move to a more favorable spot. Yet they do respond ...
... TREW Marketing , a full-service firm focused on the ... for Engineers , a free guidebook for ... Available for download on TREW Marketing,s website , the ... and outlines the firm,s proven process to grow awareness ...
Cached Biology News:Ray Semlitsch receives 2011 Fitch Award for Excellence in Herpetology 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 3TREW Marketing Introduces Smart Marketing for Engineers, a Free Guidebook for Small Businesses Targeting Technical Audiences 2
The 50 ml Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: four 50 ml tubes. ,Magnets: Neodymium rare earth permanent magnets....
...
...
...
Biology Products: